Research
Numerous clinical research studies are conducted at the CTRC Institute for Drug Development, and each patient participating in a research study is individually evaluated. After each patient gives his or her informed consent, drugs may be administered intravenously, by injection or orally. Some treatments require the patient to be admitted to one of the local hospitals participating in the Phase I research program. Each patient's progress is continually monitored by our expert team of physicians, nurses, and other medical support personnel. Participation in a clinical research study is voluntary, and a patient may withdraw from a study at any time.
See "Through a Caregiver's Eyes" a video about the passion that drives Dr. Frank Giles and the CTRC staff to develop new therapies in the fight against cancer
Should you have questions or need information about active clinical studies at the IDD, or to refer patients and/or discuss eligibility and other issues you may contact:
Patient Referral Coordinator, Drug Development Program
Phone: (210) 450-5798
Fax: (210) 616-5844
Email: onctrial@idd.org
- Research Expertise
- Numerous clinical research studies are conducted at the CTRC Institute for Drug Development, and each patient participating in a research study is individually evaluated.
- Institute for Drug Development (IDD)
- The IDD has set unprecedented standards for the development of anti-cancer agents, playing a key role in the preclinical and clinical development of new cancer drugs that were subsequently approved by the Food and Drug Administration.
- Clinical Studies
- Numerous clinical studies are conducted at the CTRC Institute for Drug Development. Here is a list of selected studies of new anticancer agents under evaluation
